Soluble Suppression of Tumorigenicity-2 Predicts Mortality and Right Heart Failure in Patients With a Left Ventricular Assist Device.
Journal Information
Full Title: J Am Heart Assoc
Abbreviation: J Am Heart Assoc
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Vascular Diseases
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Disclosures Dr Van Laake received consultancy fees from Medtronic, Abbott Vifor, and Novartis, outside the submitted work. Dr Oerlemans received consultancy fees from Alnylam, Pfizer, Johnson & Johnson, and Novartis, paid to the University Medical Center Utrecht, outside the submitted work. The remaining authors have no disclosures to report."
"Sources of Funding The collaboration project is cofunded by the public‐private partnership allowance made available by Health‐Holland, Top Sector Life Sciences and Health, to stimulate public‐private partnerships (left ventricular assist devices provide loads of valuable additional data, LSHM19035)."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025